The emergence of microbes resistant to common antibiotics represent a current treat to human health. It has been recently recognized that non-antibiotic labeled drugs may promote antibiotic-resistance mechanisms in the human microbiome by presenting a secondary antibiotic activity; hence, the development of computer-assisted procedures to identify antibiotic activity in human-targeted compounds may assist in preventing the emergence of resistant microbes. In this regard, it is worth noting that while most antibiotics used to treat human infectious diseases are non-peptidic compounds, most known antimicrobials nowadays are peptides, therefore all computer-based models aimed to predict antimicrobials either use small datasets of non-peptidic compounds rendering predictions with poor reliability or they predict antimicrobial peptides that are not currently used in humans. Here we report a machine-learning-based approach trained to identify gut antimicrobial compounds; a unique aspect of our model is the use of heterologous training sets, in which peptide and non-peptide antimicrobial compounds were used to increase the size of the training data set. Our results show that combining peptide and non-peptide antimicrobial compounds rendered the best classification of gut antimicrobial compounds. Furthermore, this classification model was tested on the latest human-approved drugs expecting to identify antibiotics with broad-spectrum activity and our results show that the model rendered predictions consistent with current knowledge about broad-spectrum antibiotics. Therefore, heterologous machine learning rendered an efficient computational approach to classify antimicrobial compounds.
Introduction
Drug-resistant microbes are one of the most important challenges for modern medicine [1] considering the increased rate in morbidity and mortality associated with antibiotic-resistant pathogens [2] . It is now commonly accepted that misuse of antibiotics is a major factor that promotes microbial resistance to these agents [3] ; such is the case of broad-spectrum antibiotics that tend to promote resistance and are now prescribed in very restricted situations [4] . Furthermore, it has been noted that many non-antibiotic human-targeted drugs alter the gut microbiome in patients taking such drugs [5, 6] . This alteration has been shown to be the consequence of a non-reported colateral antimicrobial activity, suggesting that microbe resistance to an antibiotic may emerge as The original NPCC from Maier et al. [7] , here referred to as OnlyNonPeptides, was used to build TrNPCC1 by taking only the odd listed compounds, TrNPCC2 by taking even listed compounds, TrNPCC3 and TrNPCC4, included the first and second half of the data set respectively. The OnlyPeptides data set was divided to generate TrHeterologous1, TrHeterologous2, TrHeterologous3 and TrHeterologous4 by taking the odds listed peptides, even listed peptides, first and second half, respectively. Then, these TrHeterologous1-4 data sets with peptides were combined with the TrNPCC1-4 to complete these sets. Table 2 . Testing data sets. The original NPCC from Maier et al. [7] , here referred to as OnlyNonPeptides, was used to build all Testing Sets.
Testing Set Entries Description
TeOnlyPeptides was built taking all the 861 listed compounds. TeNPCC1 and TeHeterologous1 were built by taking only the even listed compounds. TeNPCC2 and TeHeterologous2 included only the odd listed compounds. TeNPCC3 and TeHeterologous3 included the second half of OnlyNonPeptides, TeNPCC4 and TeHeterologous4 included the first half of the data set. Testing sets were built so they were the complement of the compounds listed for their Training sets, so, for example, if a training set was built using the even listed compounds (e.g., TrNPCC1), its Testing set would be built with the odd listed compounds (e.g., TeNPCC1). Heterologous Testing Sets were the same as OnlyNonPeptides Testing sets, due to the fact that the interest compounds are of non-peptidic nature.
Molecules 2019, 24, 1258 4 of 13
Five different statistical parameters (adjusted estimated error rate on the training set (AEER); correctly classified instances in the training set after splitting 33% for testing (%Split); 10-fold cross-validation (%10FCV); correctly classified instances on the testing set (%CC); area under the receiver operator characteristic curve on the testing set (AUROC)) that evaluated the performance on either the training or testing sets (see Methods) were used to identify the best classifier.
As shown in Figure 1 , the best models included heterologous compounds (peptides and NPCC): circles in Figure 1 represent heterologous training sets and accumulate on the upper part of Figure 1 , that is, those models with highest statistical parameters evaluating the model performance (the actual data in this figure for these models are included in Supplemental Table S19 ). Treating the training set rendering the best model with the K-nearest neighbor or mean-imputation approaches did not improve the performance of the best model (see Supplemental Tables S6G, S6I , S6J and its corresponding test set in Table S15G; supplemental Tables S6K, S6L and their corresponding test sets in Supplemental Tables S15I and S15J). Correctly classified instances in the test set after 67% of split validation of the training set; green circle: 10-fold cross-validation on training set; red circle: Correctly classified instances on the testing set; blue circle: AUROC on the testing set; purple circle: adjusted estimated error rate on the training set where the minimum error was represented by number 1.0) are sorted from highest to lowest values. Hence, the best parameter values are located on the left-upper part of the figure. The models using heterologous data are represented as circles; triangles are used otherwise. The actual data of this plot can be found in Supplementary Table S19.
Yet, none of these models surpassed the others in all 5 parameters. To aid in the visualization of this aspect of our results, Figure 1 displays the values in descending order from left to right; therefore, the models on the left side of the plot have better scores than those on the right. For instance, models using heterologous (represented by circles) testing sets (the red and blue circles, corresponding with the statistical parameters correctly classified instances and AUROC, respectively) laying on the left side of Figure 1 , have better performance than those models using heterologous testing sets on the right side of the plot, yet, those on the right side including either heterologous or non-heterologous training sets (green and yellow circles or triangles) have better scores than those models using heterologous or non-heterologous training sets on the left side of the plot. The models in the middle of the plot have on the other hand, intermediate performances.
Please note that the statistical parameter adjusted estimated error rate is the value that AutoWeka optimizes, hence for all the reported models is close to 1.0 and consequently does not contribute to differentiate the performance of the models. This statistical parameter is shown in Figure 1 to note Figure 1 . Classifiers performance. Five statistical parameters (yellow circle: Correctly classified instances in the test set after 67% of split validation of the training set; green circle: 10-fold cross-validation on training set; red circle: Correctly classified instances on the testing set; blue circle: AUROC on the testing set; purple circle: adjusted estimated error rate on the training set where the minimum error was represented by number 1.0) are sorted from highest to lowest values. Hence, the best parameter values are located on the left-upper part of the figure. The models using heterologous data are represented as circles; triangles are used otherwise. The actual data of this plot can be found in Supplementary Table S19 .
Yet, none of these models surpassed the others in all 5 parameters. To aid in the visualization of this aspect of our results, Figure 1 displays the values in descending order from left to right; therefore, the models on the left side of the plot have better scores than those on the right. For instance, models using heterologous (represented by circles) testing sets (the red and blue circles, corresponding with the statistical parameters correctly classified instances and AUROC, respectively) laying on the left side of Figure 1 , have better performance than those models using heterologous testing sets on the right side of the plot, yet, those on the right side including either heterologous or non-heterologous training sets (green and yellow circles or triangles) have better scores than those models using heterologous or non-heterologous training sets on the left side of the plot. The models in the middle of the plot have on the other hand, intermediate performances. Please note that the statistical parameter adjusted estimated error rate is the value that AutoWeka optimizes, hence for all the reported models is close to 1.0 and consequently does not contribute to differentiate the performance of the models. This statistical parameter is shown in Figure 1 to note that all models have similar error rates, yet different statistical parameters, hence, the best model obtained from AutoWeka cannot be selected simply by considering the error rate value reported.
Thus, to aid in the identification of the best models, we used a previous score developed by our group that takes into account multiple statistical parameters, the Combined Score or simply CScore [19] :
where MaxS n and MinS n represent the maximum and minimum scores for a given statistical parameter n over all models; S i,n is the score observed for a given statistical parameter n and model i; n represents the index of the statistical parameter to evaluate (in our case were 5 parameters: AEER, %Split, %10FCV, %CC and AUROC). Thus, formula 1 calculates CScore for each model i. CScore averages the difference of each statistical parameter to its best value (e.g., true-positive rate best value is 1, so the difference between the observed true positive rate and 1 is included in the CScore), therefore the lower the CScore value the better the classifying model. Figure 2 ( and Supplementary  Table S20) shows that the five best models are those using heterologous training sets (the ones below the 0.3 line in Figure 2 ). Furthermore, we noticed that the top 5 best models overlapped on average in more than 70% of their classifications hence, these were mainly redundant (see Figure 3 ). that all models have similar error rates, yet different statistical parameters, hence, the best model obtained from AutoWeka cannot be selected simply by considering the error rate value reported.
where MaxSn and MinSn represent the maximum and minimum scores for a given statistical parameter n over all models; Si,n is the score observed for a given statistical parameter n and model i; n represents the index of the statistical parameter to evaluate (in our case were 5 parameters: AEER, %Split, %10FCV, %CC and AUROC). Thus, formula 1 calculates CScore for each model i.
CScore averages the difference of each statistical parameter to its best value (e.g., true-positive rate best value is 1, so the difference between the observed true positive rate and 1 is included in the CScore), therefore the lower the CScore value the better the classifying model. Figure 2 ( and Supplementary Table S20) shows that the five best models are those using heterologous training sets (the ones below the 0.3 line in Figure 2 ). Furthermore, we noticed that the top 5 best models overlapped on average in more than 70% of their classifications hence, these were mainly redundant (see Figure 3) . A circle represents each model; the best model has the lowest CScore. The line represents the CScore = 0.3, that separates the top 5 models from the rest. The models using heterologous data are represented as circles; triangles are used otherwise. The actual data of this plot can be found in Supplementary Table S20 . Figure 3 . Classifiers overlap. The predictions of antimicrobial compounds of the top 5 models were compared to quantify their overlap. The image shows the 10 pairs of models generated from these 5 top models. The comparison was performed on the discovery set (see Methods) because not every model had the same testing set.
Therefore, we selected the best model based on the lowest CScore; such model was built using the RandomCommittee algorithm (see Supplemental Table S21 for the algorithm parameters) on the TrHeterologous1 set (see Table 1 Table S21 ; the corresponding data set for this model is reported in Supplemental Table S6E ).
Identifying Broad-Spectrum Antibiotics among FDA-Approved Compounds
We used the best model to predict NPCC with expected gut antimicrobial activity among FDA-approved drugs. The motivation to perform this prediction is not for testing purposes, as in the case of the training and testing sets used before. Hence, the set of compounds used in this prediction stage is referred to as the discovery set, because we aimed to discover potential compounds with gut antimicrobial activity. We used 756 FDA-approved compounds included in the ZINC database (see Methods) that were not part of the training or testing sets; these compounds included 111 antimicrobials and 645 compounds without any known antimicrobial activity; we also added 73 NPCC that included 22 antifungal compounds and 51 without any reported antifungal activity (see Supplementary Table S22) . We have previously reported that these 22 antifungals work through a mechanism (alter calcium intake [20] ) different from antibacterial compounds (e.g., penicillin derivates, sulphonamides, etc), thus we expected our model to predict few of these compounds as antibacterials. FDA-approved compounds on the other hand are expected not to have, or to have minor, gut antimicrobial activity otherwise their secondary gastrointestinal effects Figure 3 . Classifiers overlap. The predictions of antimicrobial compounds of the top 5 models were compared to quantify their overlap. The image shows the 10 pairs of models generated from these 5 top models. The comparison was performed on the discovery set (see Methods) because not every model had the same testing set.
We used the best model to predict NPCC with expected gut antimicrobial activity among FDA-approved drugs. The motivation to perform this prediction is not for testing purposes, as in the case of the training and testing sets used before. Hence, the set of compounds used in this prediction stage is referred to as the discovery set, because we aimed to discover potential compounds with gut antimicrobial activity. We used 756 FDA-approved compounds included in the ZINC database (see Methods) that were not part of the training or testing sets; these compounds included 111 antimicrobials and 645 compounds without any known antimicrobial activity; we also added 73 NPCC that included 22 antifungal compounds and 51 without any reported antifungal activity (see Supplementary Table S22) . We have previously reported that these 22 antifungals work through a mechanism (alter calcium intake [20] ) different from antibacterial compounds (e.g., penicillin derivates, sulphonamides, etc), thus we expected our model to predict few of these compounds as antibacterials. FDA-approved compounds on the other hand are expected not to have, or to have minor, gut antimicrobial activity otherwise their secondary gastrointestinal effects would be significant. We would expect that FDA-approved drugs would be less likely predicted to act against non-athogenic gut microbes than antifungals. To evaluate the reliability of our predictions using the discovery set, we considered that antibiotic compounds against the non-pathogenic gut flora among the FDA-approved drugs should be considered broad-spectrum antibiotics; please note that our classifier was not trained to predict this class of antibiotics, yet the combination of the predictions of our classifier on the FDA-approved drugs would render this information. The definition of broad-spectrum antibiotics is somehow arbitrary, for instance, it is considered that antibiotics that act on G(+) and G(−) are broad-spectrum antibiotics for some authors, while those acting against pathogenic and non-pathogenic microorganisms are classified as broad-spectrum antibiotics by others [21, 22] . The list of broad-spectrum antibiotics was obtained from five recent works (see Methods), including 19 broad-spectrum and 3 narrow-spectrum antibiotics (see Supplementary Table S22 ). We were able to identify 72 true positives (FDA-approved antibiotics against pathogenic microbes predicted to act against non-pathogenic gut microbes) in the discovery set that we predicted should be considered as broad-spectrum antibiotics (see Table 3 ). The actual data for this table can be found in Supplementary Table S22 . From these 72 antimicrobials, only 16 had been annotated as broad-spectrum antibiotics and 3 as narrow-spectrum antibiotics (see Supplemental Table S22 ). Hence, we propose that these 3 annotated narrow-spectrum antibiotics should be considered more likely as broad-spectrum antibiotics (see Table 4 ). Table 4 . True pathogenic antimicrobials predicted by the best classifier on the discovery set.
Compound Name Annotation
Amoxicillin Narrow spectrum Phenoxymethylpenicillin Narrow spectrum Cephalexin Narrow spectrum
On the other hand, among the 61 false negatives, 3 compounds were annotated as broad-spectrum antibiotics (see Supplemental Table S22 ). This annotation is consistent with our predictions, since these antibiotics directed towards pathogenic microorganisms are unlikely to affect the non-pathogenic gut microbes. Furthermore, 17 out of the 22 antifungal compounds were predicted as antimicrobials.
Thus, in total we were able to correctly identify 16 out of the 19 known broad-spectrum antibiotics and we suggest that 3 of the annotated narrow-spectrum antibiotics should be re-evaluated; hence, the reliability to identify broad-spectrum antibiotics was 84.2%. Furthermore, our results suggest that 56 (61 true negatives less 5 antifungals) (50.4%) out of 111 antibiotics approved by the FDA included in our discovery set are unlikely to affect gut microbes. In comparison, 5 (22.7%) out of 22 antifungals were predicted not to act against the gut microbes (see Supplemental Table S21 ). Thus, it is twice as much less likely that FDA-approved antibiotics would be toxic against gut microbes than antifungals.
Discussion
The identification of antimicrobial compounds assisted by machine-learning techniques has multiple advantages, such as reduction of the invested time to develop novel pharmaceuticals or to flag molecules that could have secondary antimicrobial activity [17] . An important aspect of these techniques is how to improve the reliability of these predictions. One way to achieve this is to increase the number of examples in the training and testing sets. In this work we propose that it is possible to use chemical compounds of different nature (peptides and NPCC) that are commonly modeled separately as antimicrobials to improve the reliability of the predictions. Here we show that indeed, the training sets that rendered the best classifiers of antimicrobial compounds were heterologous, those including NPCC and peptides (see Figures 1 and 2) . We can compare our best classifier with previous works in terms of the learnability of our classes, that is, how well gut antimicrobial compounds are differentiated from non-antimicrobial gut compounds. In that sense, the numeric performance achieved by the best classifier on the testing set (AUC = 0.83) is comparable with the performance achieved with one of the best antimicrobial peptide classifiers (AUC = 0.85) recently reported [23] , indicating that the learnability of heterologous training sets is as good as those of only peptides.
Another important aspect of our work is the molecular descriptors obtained to best classify gut antimicrobial compounds that included both peptides and NPCC. Although our goal was not to identify common descriptors for NPCC and peptides (these are already calculated by available packages, see Methods), we did look for those descriptors that are relevant to learn the difference between antimicrobials from non-antimicrobials. Our results indicate that the solution to this problem requires the transformation of 86 computed molecular descriptors, suggesting that other molecular descriptors, most likely associated to these 86 descriptors, may improve the current best-model performance.
In terms of improving the performance reported in this work, it is worth mentioning that we used peptides that were not tested by Maier et al. [7] yet, these peptides had reported antibiotic activity against at least one microorganism (Escherichia coli) found in the gut and tested by Maier and collaborators. On the other hand, the NPCC included in our work had antibiotic activity against at least one of the 40 gut microorganisms tested by Maier and collaborators. Hence, one alternative approach to improve the performance of classifiers aimed at identifying gut microorganisms would be to include antibiotics that target more common gut microorganisms; that would require further experimental data that is not currently available at present.
To the best of our knowledge, no previous machine-learning efforts to assist in the identification of broad-spectrum antibiotics have been reported; here the definition of broad-spectrum antibiotics was restricted to those acting against both pathogenic and non-pathogenic microorganisms. Hence, using a classifier trained to identify gut non-pathogenic antimicrobial compounds to predict this activity in FDA-approved antibiotics targeted against pathogenic microorganisms represents a way to identify broad-spectrum antibiotics. Our results suggest that half of the FDA-approved antibiotics are likely to have antimicrobial activity against the gut microorganisms indicating that these require further testing or investigation. For instance, two annotated narrow-spectrum antibiotics, amoxicillin and cephalexin, that were predicted to alter gut microbes are known to affect the gastrointestinal flora [24] . On the other hand, the broad-spectrum antibiotic ceftaroline fosamil recently approved by the FDA to treat bacterial pneumonia and skin infections, which was not predicted to affect the gut flora, was reported to have minor gastrointestinal effects during clinical trials [25] .
How significant is our finding that almost half of the FDA-approved antibiotics are predicted to have a broad-spectrum activity? To address this question, we included in the discovery set a group of antifungal compounds. All microorganisms used to train our models were bacteria, hence we expected that these antifungals that act through a mechanism different from those reported for bacteria would be unlikely predicted to act against bacteria; lets refer to this negative prediction as expectation-antifungal. On the other hand, most FDA-approved antibiotics should unlikely present antibiotic activity against gut microbes, otherwise these would frequently have secondary gastrointestinal effects on patients; lets refer to this negative prediction as expectation-FDA. Then, to address the significance of our findings about broad-spectrum antibiotics requires evaluating expectation-antifungal and expectation-FDA; if FDA-approved drugs are less likely to act on gut microbes than antifungals then expectation-FDA < expectation-antifungal. Indeed, we observed that FDA-approved antibiotics are twice as much less likely to act against gut microbes than antifungals. Thus, our results indicate that even when FDA-approved antibiotics are safer (do not act against non-pathogenic resident gut bacteria) than our control group (antifungals), we identified some of these compounds that need to be re-assessed as potential promoters of resistance among microbes for their potential broad-spectrum activity.
In summary, we report a computational approach to use heterologous antimicrobial compounds (peptides and non-peptides) to improve the discriminatory power of machine-learning approaches. We show that training a classifier to identify antibiotics against the gut flora using heterologous training sets correctly anticipate adverse gastrointestinal reactions in patients receiving these antibiotics.
Materials and Methods

Materials
Peptides included in the training sets were obtained from the non-redundant data set of 20 public databases (see Table 5 ). Testing sets were derived from the work reported by Maier and collaborators (see Supplemental Tables S10-S18 ). Finally, a discovery set containing 750 FDA-approved drugs for treating human infectious diseases and 76 antifungal drugs was built from the ZINC database [26] . Molecular descriptors were computed with PadelDescriptor [27] . For every training and test set, we performed five different approaches to process the molecular descriptors for each peptide and/or NPCC. These included: no processing; eliminate every null value; substitute every "Infinity" value for 0 or 99,999,999; reduction of the dimensionality applying a principal component analysis implemented in WEKA package (see below). Since the substitution of Infinity values for 0 or 99,999,999 is not a conventional strategy, we performed an imputation of the Infinity and null values using the K nearest neighbor or mean imputation approaches, but only on the best model data set for comparison. That is, from the 9 training sets we generated a total of 45 training sets following the different approaches described before; the same applies to the 9 testing sets. For the discovery set only the transformation applied to the best classifier was performed. 
Method
To identify the best model to classify gut antimicrobial compounds, we followed a systematic method previously reported by our group [46] . Briefly, given the training sets, 52 different machine-learning algorithms implemented in WEKA [47] and their parameters were systematically analyzed to identify the algorithm, parameters and molecular descriptors that renders the lowest possible error in classification; this systematic analysis was performed by the Bayesian optimization algorithm implemented in AutoWEKA [48] . We ran AutoWEKA against any training set for 10, 90, 720, 2880 and 4320 minutes to identify when the optimization has reached a plateau in the classification error. Afterwards, a 10-fold cross validation and 67% split tests were performed in WEKA. Finally, these classifiers were evaluated against their corresponding testing sets. Two statistical parameters were chosen to evaluate the performance of the classifiers during the testing, including: Area under the ROC curve and correctly classified instances on the testing set. Therefore, a total of 5 statistical parameters were used to define the best classifiers, three for the training phase (adjusted estimated error rate on the training set; correctly classified instances in the training set after splitting 33% for testing; 10-fold cross-validation) and two for the testing phase (AUROC and correctly classified instances).
To identify the intersection set between the top 5 classifiers, we compared the predictions of these classifiers rendering 10 possible pairs of predictions on the discovery set; we used this set because not every classifier had the same testing set. The best model was identified using a combined score (see formula 1): the model with the lowest combined score was chosen. The model then was used to predict gut antimicrobial compounds in the discovery set using WEKA command line (see Supplemental File S1). To annotate as broad-spectrum or narrow-spectrum antibiotics, we used five different previous works that classified antibiotic action [22, [49] [50] [51] [52] .
Supplementary Materials: The following are available online at http://bis.ifc.unam.mx:8080/ironbios/ heteroml/, File S1: Script to execute the best model to predict antimicrobials on FDA-approved drugs, Table S19 : Parameter values for all models tested, Table S20 : CScore values for all model tested, Table S21 : Best models algorithms and corresponding parameters and Table S22 
